Allarity Ebitda from 2010 to 2024

ALLR Stock  USD 1.26  0.07  5.88%   
Allarity Therapeutics EBITDA yearly trend continues to be relatively stable with very little volatility. EBITDA is likely to drop to about -12.7 M. During the period from 2010 to 2024, Allarity Therapeutics EBITDA destribution of quarterly values had r-value of (0.41) from its regression line and median of (10,059,000). View All Fundamentals
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
-12.1 M
Current Value
-12.7 M
Quarterly Volatility
4.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Allarity Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Allarity Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 543.9 K, Interest Income of 36.2 K or Depreciation And Amortization of 35.1 K, as well as many indicators such as Price To Sales Ratio of 229, Dividend Yield of 0.0 or Days Sales Outstanding of 4 K. Allarity financial statements analysis is a perfect complement when working with Allarity Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Allarity Therapeutics Correlation against competitors.
To learn how to invest in Allarity Stock, please use our How to Invest in Allarity Therapeutics guide.

Latest Allarity Therapeutics' Ebitda Growth Pattern

Below is the plot of the Ebitda of Allarity Therapeutics over the last few years. It is Allarity Therapeutics' EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Allarity Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

Allarity Ebitda Regression Statistics

Arithmetic Mean(11,634,610)
Coefficient Of Variation(39.31)
Mean Deviation2,850,361
Median(10,059,000)
Standard Deviation4,573,989
Sample Variance20.9T
Range19.9M
R-Value(0.41)
Mean Square Error18.7T
R-Squared0.17
Significance0.13
Slope(420,329)
Total Sum of Squares292.9T

Allarity Ebitda History

2024-12.7 M
2023-12.1 M
2022-17.2 M
2021-25.9 M
2020-6 M

About Allarity Therapeutics Financial Statements

Allarity Therapeutics shareholders use historical fundamental indicators, such as Ebitda, to determine how well the company is positioned to perform in the future. Although Allarity Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Allarity Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Allarity Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
EBITDA-12.1 M-12.7 M

Pair Trading with Allarity Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allarity Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allarity Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Allarity Stock

  0.9VALN Valneva SE ADR Downward RallyPairCorr

Moving against Allarity Stock

  0.66KZR Kezar Life SciencesPairCorr
  0.6MLYS Mineralys Therapeutics, Downward RallyPairCorr
The ability to find closely correlated positions to Allarity Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allarity Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allarity Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allarity Therapeutics to buy it.
The correlation of Allarity Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allarity Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allarity Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allarity Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Allarity Stock Analysis

When running Allarity Therapeutics' price analysis, check to measure Allarity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allarity Therapeutics is operating at the current time. Most of Allarity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allarity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allarity Therapeutics' price. Additionally, you may evaluate how the addition of Allarity Therapeutics to your portfolios can decrease your overall portfolio volatility.